Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4419-4429

  Lin, Li Gen ^a   Xie, Hua ^a   Li, Hong Lin ^a   Tong, Lin Jiang ^a   Tang, Chun Ping ^a   Ke, Chang Qiang ^a   Liu, Qun Fang ^a   Lin, Li Ping ^a   Geng, Mei Yu ^a   Jiang, Hualiang ^a   Zhao, Wei Min ^a   Ding, Jian ^a   Ye, Yang ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEOXY O METHYSAPPANOL; 3' DEOXY SAPPANONE A; 4 O METHYLEPIHEMATOXYLOL; 4 O METHYLHEMATOXYLOL; 4 O METHYLSAPPANOL; BONDUCELLIN; BUTEIN; DEOXY SAPPANCHALCONE; EPIHEMATOXIN; EPIHEMATOXYLOL; EUCOMIN; HEAMATOXYLON CAMPECHIANUM EXTRACT; HEMATOXIN; HEMATOXYLENE; HEMATOXYLIN; HEMATOXYLOL; HEMATOXYLONE; ISOBAVACHALCONE; ISOFLAVONOID; ISOHEMATOXYLIN; ISOLIQUIRITIGENIN; NATURAL PRODUCT; PLANT EXTRACT; PROTEIN TYROSINE KINASE INHIBITOR; PROTOSAPPANIN A; SAPPANCHALCONE; SAPPANOL; SAPPANONE A; SAPPANONE B; SAPPENENE; UNCLASSIFIED DRUG;

ARTICLE; AUTOANALYSIS; BIOLOGICAL ACTIVITY; CELL STRAIN HT29; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HEAMATOXYLON CAMPECHIANUM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MASS SPECTROMETRY; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DOCKING; ONCOGENE SRC; PROTON NUCLEAR MAGNETIC RESONANCE; SIMULATION; STEADY STATE; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ADENOSINE TRIPHOSPHATE; CELL LINE, TUMOR; CELL-FREE SYSTEM; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FABACEAE; FLAVONOIDS; HEMATOXYLIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449108208     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701501x     Document Type: Article

References (32)

1. Traxler, P.; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 2001, 21, 499-512.
2. Baselga, J. Targeting tyrosine kinases in cancer: the second wave. Science 2006, 312, 1175-1178.
3. Plested, J. S.; Coull, P. A.; Gidney, M. A. ELISA Methods. Mol. Med. 2003, 71, 243-261.
4. Zhang, X. H.; Guo, X. N.; Zhong, L.; Luo, X. M.; Jiang, H. L.; Lin, L. P.; Ding, J. Establishment of the active catalytic domain of human PDGFRβ tyrosine kinase-based ELISA assay for inhibitor screening. Biochim. Biophys. Acta. 2007, 1770, 1490-1497.
5. Irby, R. B.; Yeatman, T. J. Role of Src expression and activation in human cancer. Oncogene 2000, 19, 5636-5642.
6. Armstrong, W. P. Logwood and brazilwood: trees that spawned two nations. Pac. Hortic. 1992, 53, 38-43.
7. Brown, M. T.; Cooper, J. A. Regulation, substrates and functions of Src. Biochim. Biophys. Acta 1996, 1287, 121-149.
8. Namikoshi, M.; Nakata, H.; Nuno, M.; Ozawa, T.; Saitoh, T. Homoisoflavonoids and related compounds. III. Phenolic constitution of Caesalpinia japonica SIEB et ZUCC. Chem. Pharm. Bull. 1987, 35, 3568-3575.
9. Namikoshi, M.; Nakata, H.; Yamada, H.; Nagai, M.; Saitoh, T. Homoisoflavonoids and related compounds. II. Isolation and absolute configurations of 3,4-dihydroxylated homoisoflavonoids and brazilins from Caesalpinia sappan L. Chem. Pharm. Bull. 1987, 35, 2761-2773.
10. Namikoshi, M.; Nakata, H.; Saitoh, T. Homoisoflavonoids from Caesalpinia sappan. Phytochemistry 1987, 26, 1831-1833.
11. Purushothaman, K. K.; Kalyani, K.; Subramaniam, K. Structure of bonducellin: a new homoisoflavonoids from Caesalpinia bonducella. India J. Chem. Sect. B: Org. Chem. Incl. Med. Chem. 1982, 21, 383.
12. Heller, W.; Andermatt, P.; Schaad, W. A.; Tamm, E. Homoisoflavonone IV. Neue inhaltsstoffe der eucomin-reihe von Eucomis bicolor. Helv. Chim. Acta 1976, 59, 2048-2058.
13. Kobayashi, M.; Noguchi, H.; Sankawa, U. Formation of chalcones and isoflavones by callus culture of Glycyrrhiza uralensis with different production patterns. Chem. Pharm. Bull. 1985, 33, 3811-3816.
14. Nagai, M.; Nagumo, S.; Lee, S.-M.; Eguchi, I.; Kawai, K.-I. Protosappanin A, a novel biphenyl compound fromx Sappan Lignum. Chem. Pharm. Bull. 1986, 34, 1-6.
15. Masuda, H.; Ohtani, K.; Mizutani, K.; Ogawa, S.; Kasai, R.; Tanaka, O. Chemical study on Haematoxylon campachianum: a sweet principle and new dibenz[b,d]oxocin derivatives. Chem. Pharm. Bull. 1991, 39, 1382-1384.
16. Namikoshi, M.; Saitoh, T. Homoisoflavonoids and related compounds. IV. Absolute configurations of homoisoflavonoids from Caesalpinia sappan L. Chem. Pharm. Bull. 1987, 35, 3597-3602.
17. Shimokawa, T.; Kinjo, J.-E.; Yamahara, J.; Yamasaki, M.; Nohara, T. Two novel aromatic compounds from Caesalpinia sappan. Chem. Pharm. Bull. 1985, 33, 3545-3547.
18. Nicholls, K. W.; Bohm, B. A. Flavonoids and affinities of Coreopsis bigelovii. Phytochemistry 1979, 18, 1076.
19. Sequist, L. V. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007, 12, 325-330.
20. Fischer, O. M.; Streit, S.; Hart, S.; Ullrich, A. Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol. 2003, 7, 490-495.
21. Scagliotti, G. V. Potential role of multitargeted tyrosine kinase inhibitors in non-small-cell lung cancer. Ann. Oncol. 2007, 18 (Suppl 10), 32-41.
22. Stein, M. N.; Flaherty, K. T. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin. Cancer Res. 2007, 13, 3765-3770.
23. Atkins, M.; Jones, C. A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discovery 2006, 5, 279-280.
24. Titford, M. The long history of hematoxylin. Biotech. Histochem. 2005, 80, 73-78.
25. Breitenlechner, C. B.; Kairies, N. A.; Honold, K.; Scheiblich, S.; Koll, H.; Greiter, E.; Koch, S.; Schäfer, W.; Huber, R.; Engh, R. A. Crystal structures of active Src kinase domain complexes. J. Mol. Biol. 2005, 353, 222-231.
26. Roskoski, R., Jr. Src protein-tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun. 2004, 324, 1155-1164.
27. Zhong, L.; Guo, X. N.; Zhang, X. H.; Wu, Z. X.; Luo, X. M.; Jiang, H. L.; Ding, J. Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening. Biochim. Biophys. Acta 2005, 1722, 254-261.
28. Guo, X. N.; Zhong, L.; Tan, J. Z.; Li, J.; Luo, X. M.; Jiang, H. L.; Ding, J. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with antitumor and anti-angiogenic effects. Cancer Biol. Ther. 2005, 4, 1125-1132.
29. Breitenlechner, C. B.; Kairies, N. A.; Honold, K.; Scheiblich, S.; Koll, H.; Greiter, E.; Koch, S.; Schäfer, W.; Huber, R.; Engh, R. A. Crystal structures of active SRC kinase domain complexes. J. Mol. Biol. 2005, 353, 222-231.
30. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235-242.
31. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
32. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A Second Generation Force-Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.